Bristol Myers Squibb (BMS) has entered a multi-year agreement with Faro to use AI-powered workflows for improving clinical trial protocols, covering trial design, drafting, validation, and optimization.17
The partnership supports both early- and late-phase programs and aims to scale AI deployment across BMS's global development efforts using structured digital protocols.17
Faro, based in San Diego, specializes in AI for biopharma trial processes and benchmarks protocols against industry standards like the Tufts CSDD framework.1
The announcement was made on March 31, 2026, aligning with BMS's broader AI initiatives, including recent partnerships with Evinova, Microsoft, and others.125
Sources:
1. https://www.fiercebiotech.com/cro/bms-and-faro-join-forces-streamline-clinical-development
2. https://evinova.com/press-releases/evinova-bristol-myers-squibb-partnership
5. https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Collaboration-with-Microsoft-to-Advance-AI-Driven-Early-Detection-of-Lung-Cancer/default.aspx
7. https://www.streetinsider.com/EZ+Newswire/Faro+Announces+Collaboration+with+Bristol+Myers+Squibb+to+Scale+Autonomous+AI+in+Clinical+Development/26246798.html